New injection for kids with lupus shows promise in small study
NCT ID NCT05917288
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how a lupus medicine called belimumab works in Chinese children aged 5 to 17 who had already received the IV form for 48 weeks. The goal was to check the drug levels in the blood and see if switching to a shot under the skin is safe. Sixteen children took part, and the results help doctors understand the right dose for different body weights.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Beijing, 100045, China
-
GSK Investigational Site
Changsha, 410007, China
-
GSK Investigational Site
Hangzhou, 310052, China
-
GSK Investigational Site
Nanjing, 210011, China
-
GSK Investigational Site
Shanghai, 361006, China
-
GSK Investigational Site
Suzhou, 215007, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smartphone app bridge the lupus care gap for women of color?
- Blood traps may reveal lupus kidney treatment success
- Can a peer coach help young people take control of their chronic illness?
- Lupus patients may get a boost from doctors checking their prescription refill records
- Engineered immune cells take aim at Hard-to-Treat autoimmune diseases
- New Four-Pronged antibody takes aim at lupus